Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- European Mantle Cell Lymphoma Network
- Target Recruit Count
- 360
- Registration Number
- NCT00209222
- Locations
- 🇫🇷
Groupe D´Etudes des Lymphomes De l´Adulte (GELA), Paris, France
🇩🇪German Low Grade Study Group (Glsg), Munich, Germany
🇵🇱The Maria Sklodowska Memorial, Cancer Center - Inst. of Oncology, Warszawa, Poland
Prevention Trial of Nosocomial Infections in Neutropenic Prematures With G-CSF
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- University Hospital, Strasbourg, France
- Target Recruit Count
- 200
- Registration Number
- NCT00213759
- Locations
- 🇫🇷
André Labbe, Clermont-Ferrand, France
🇫🇷Alain Menget, Besancon, France
🇫🇷Marie Thieuleux, Calais, France
Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Centre National de Greffe de Moelle Osseuse
- Target Recruit Count
- 160
- Registration Number
- NCT00207792
- Locations
- 🇹🇳
Centre National de Greffe de Moelle Osseuse, Tunis, Tunisia
Efficacy of G-CSF-Priming in Elderly AML Patients
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-10-26
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT00199147
- Locations
- 🇩🇪
University Hospital, Medical Department II, Frankfurt, Germany
German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-08-23
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT00199017
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: DexamethasoneDrug: VincristineDrug: DaunorubicinDrug: AsparaginaseDrug: MethotrexateDrug: CytarabineDrug: MercaptopurineDrug: G-CSFDrug: VindesineDrug: EtoposideDrug: PrednisoloneDrug: AdriamycinDrug: ThioguanineDrug: TeniposideProcedure: CNS irradiationProcedure: Mediastinal IrradiationProcedure: Stem cell transplantation (SCT)Drug: IdarubicinDrug: FludarabineDrug: Cladribine
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1883
- Registration Number
- NCT00198991
- Locations
- 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Nicola Goekbuget
- Target Recruit Count
- 650
- Registration Number
- NCT00199082
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-08-23
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00199004
- Locations
- 🇩🇪
University Hospital of Frankfurt, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 225
- Registration Number
- NCT00199056
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 80
- Registration Number
- NCT00194753
- Locations
- 🇺🇸
University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.